Hikma Pharmaceuticals said its US unit had launched its cancer treatment Mitomycin for injection.
The treatment was not recommended as single-agent, primary therapy but had been shown to be useful in treating disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents.
It was also useful as palliative treatment when other modalities had failed.
'We are excited to add Mitomycin for injection to our oncology portfolio in the US, improving patients' access to this important medicine,' injectables president Riad Mechlaoui said.
'This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.'
At 1:07pm: (LON:HIK) Hikma Pharmaceuticals PLC share price was +19.25p at 1529.75p